Skip to Content

Treatment of Autoimmune Patients with CD19-CAR T Cells Results in Long-Term Drug-Free Remission or No Progression

Fabian Müller from the University Clinic of Erlangen presented updated data on the treatment of autoimmune patients with CD19-CAR T-cell therapy at ASH 2024. Data from 35 patients demonstrated a 100% remission rate at six months with a strong safety profile and deep B-cell depletion. Long-term follow-ups revealed long-term drug-free remission or no progression, with disease recurrence in only one patient

Fabian Müller

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top